Insys Therapeutics (INSY) Stock Rating Lowered by Piper Jaffray Companies

Piper Jaffray Companies lowered shares of Insys Therapeutics (NASDAQ:INSY) from a neutral rating to an underweight rating in a research note issued to investors on Friday morning, MarketBeat Ratings reports.

INSY has been the subject of several other research reports. Zacks Investment Research downgraded shares of Insys Therapeutics from a hold rating to a sell rating in a research report on Saturday, February 3rd. ValuEngine raised shares of Insys Therapeutics from a sell rating to a hold rating in a research report on Friday, December 29th. Oppenheimer reissued a hold rating on shares of Insys Therapeutics in a research report on Sunday, November 12th. Finally, Cann reissued an average rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $9.38.

Shares of Insys Therapeutics (INSY) opened at $7.28 on Friday. The firm has a market cap of $534.11, a price-to-earnings ratio of -2.31 and a beta of 1.02. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.47). Insys Therapeutics had a negative return on equity of 19.79% and a negative net margin of 162.07%. The company had revenue of $31.49 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the prior year, the company earned $0.03 EPS. The firm’s revenue was down 42.6% on a year-over-year basis.

Several hedge funds have recently modified their holdings of INSY. Dynamic Technology Lab Private Ltd bought a new stake in shares of Insys Therapeutics during the third quarter worth $119,000. Janney Montgomery Scott LLC bought a new position in Insys Therapeutics in the third quarter valued at $135,000. Stone Ridge Asset Management LLC bought a new position in Insys Therapeutics in the fourth quarter valued at $137,000. Voya Investment Management LLC bought a new position in Insys Therapeutics in the second quarter valued at $149,000. Finally, Royal Bank of Canada grew its position in Insys Therapeutics by 100.9% in the second quarter. Royal Bank of Canada now owns 13,695 shares of the specialty pharmaceutical company’s stock valued at $173,000 after purchasing an additional 6,877 shares in the last quarter. 24.19% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply